Building equitable epidemic response: the Interdisciplinary Consortium for Epidemics Research (ICER) position on Bundibugyo ebolavirus and regional preparedness in sub-Saharan Africa.

Authors

Misaki Wayengera, Patrick D M C Katoto, Wilber Sabiiti, Winters Muttamba, Bayode Romeo Adegbite, Samuel Lwamushi Makali, Elias N Nyanda, Placide K Mbala, Duncan Chanda, Willy Ssengooba, Haruna Muwonge, Hakim Sendagire, Bariki Mtafya, Denis Niyomwungere, Shema Hugor, Andrew Nsawotebba, Mudarshiru Bbuye, Jean Pierre Musabyimana, Barnabas Bakamutumaho, Henry Kyobe Bosa, Daniel Kiiza, Omu Anzala, David Lupande Mwenebitu, Archippe Muhandule Birindwa, Chiza Rogers, Gerard Jacques Mparanyi, Brenda Nakazibwe, Mosoka Papa Fallah, Pauline Byakika-Kibwika, Kariuki Njenga, Bruce Kirenga, Interdisciplinary Consortium for Epidemics Research

Published in

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Pages 109163. Oct 12, 2026. Epub Oct 12, 2026.

Abstract

The 2014-16 West African Ebola epidemic exposed consequences of weak regional preparedness and limited local scientific leadership. The Bundibugyo ebolavirus (BDBV) outbreak in the Democratic Republic of the Congo (DRC), with spill over into Uganda threatens to follow the same trend. Beyond the immediate response, this crisis is a defining moment for a question the region can no longer defer: who leads the science when Africa faces epidemics? As a scientific response, we argue for an immediate, regionally led research programme. To do this, ICER makes five priority positions: 1) Conduct of hypothesis-driven research as BDBV is understudied and yet is a high-risk and not a benign strain pathogen, 2) Rapid regional expansion is a realistic scenario, hence respective governments' preparedness frameworks must expedite to accommodate such an expansion, 3) African-led science is essential to an effective response, not merely an equity aspiration but a preparedness imperative, 4) Diagnostic, therapeutic, and vaccine development for BDBV cannot await commercial incentives and must be initiated proactively by public institutions, 5) An equitable partnership encompassing local leadership, fair authorship, capacity enhancement, and benefit sharing, is a prerequisite to be negotiated before research begins, and not an afterthought.

PMID:
42863700
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.